Diligence memo · auto-generated · as of July 2, 2026
NuSirt Sciences Inc.
NuSirt Sciences Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
NuSirt Sciences Inc. operates in Pharmaceuticals, based in NASHVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NuSirt Sciences Inc. has raised $8.1M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.0M on 2015-09-30.
Most recent recorded round closed around 2016-11-22.
Valuation (modeled)modeled
Provath models NuSirt Sciences Inc. at approximately $62M (range $2.3M–$337M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.35× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 9.6 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 50% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 46% of those peers.
Closest niche peers: Arbutus Biopharma Corp, Rvc 360, Llc, Sterrx, Llc, Ribometrix, Inc., Neuraltus Pharmaceuticals, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.